

This article was downloaded by:

On: 30 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## **Spectroscopy Letters**

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597299>

## **Fluorometric and Derivative Spectrophotometric Determination of Norfloxacin**

M. Stankov<sup>a</sup>; D. Stankov<sup>b</sup>; Z. Milićević<sup>a</sup>; D. Veselinović<sup>c</sup>; P. Djurdjević<sup>d</sup>

<sup>a</sup> Faculty of Pharmacy, <sup>b</sup> Biochemistry Department, Hospital "Dr. Dragiša Mišović", <sup>c</sup> Faculty of Physical Chemistry, Belgrade <sup>d</sup> Faculty of Science, Kragujevac, Yugoslavia

**To cite this Article** Stankov, M. , Stankov, D. , Milićević, Z. , Veselinović, D. and Djurdjević, P.(1993) 'Fluorometric and Derivative Spectrophotometric Determination of Norfloxacin', *Spectroscopy Letters*, 26: 9, 1709 — 1714

**To link to this Article:** DOI: 10.1080/00387019308010769

**URL:** <http://dx.doi.org/10.1080/00387019308010769>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

FLUOROMETRIC AND DERIVATIVE SPECTROPHOTOMETRIC  
DETERMINATION OF NORFLOXACIN

**Key words:** fluorometry, derivative spectrophotometry, serum, tablets, norfloxacin analysis

M. Stankov,<sup>1</sup> D. Stankov,<sup>2</sup> Z. Milićević, D. Veselinović,<sup>3</sup> P. Djurdjević<sup>4</sup>

<sup>1</sup>Faculty of Pharmacy, <sup>2</sup>Hospital "Dr. Dragiša Mišović", Biochemistry Department,

<sup>3</sup>Faculty of Physical Chemistry, Belgrade, <sup>4</sup>Faculty of Science, Kragujevac, Yugoslavia

ABSTRACT

The method for the direct determination of norfloxacin, without prior separation, in serum and pharmaceutical formulations, by means of fluorometry and second derivative u.v. spectrophotometry, was developed. Fluorometric assay of norfloxacin in serum was carried in 0.1 M HCl, with the addition of sodium-dodecylsulphate, at emission wavelength 450 nm (excitation 320 nm). Linear calibration curve was obtained in the concentration range 20 - 320  $\mu\text{g/L}$  with the detection limit 2  $\mu\text{g/L}$ . The second derivative spectrophotometry was used for the determination of the norfloxacin in tablets at 337 nm using 0.05 M NaOH as solvent. Detection limit was 30  $\mu\text{g/L}$ .




Fig. 1. Chemical structure of norfloxacin

## INTRODUCTION

Norfloxacin, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinolinecarboxylic acid (Fig.1.) is a fluoroquinolone antibiotic that exhibits strong bactericidal activity against both, Gram-positive and Gram-negative bacteria, in vitro and in vivo.

The mechanism of its action is based on the inhibition of the DNA-gyrase (topoisomerase II) of bacteria. However its absorption, after oral administration is incomplete thus leading to the reduced bio-availability. So far, there were only few literature data of the direct quantitative assay (without prior extraction) of some fluoroquinolones in biological samples and pharmaceutical formulations based on HPLC [1] and fluorometric [2] determinations. The most commonly employed methods for the determination of norfloxacin are HPLC [4, 5, 8-10, 13, 14], DPP polarography [3], spectrofluorimetry [7, 11] and spectrophotometry [6, 12]. It is therefore of interest to develop fast and simple procedures for quantification of the norfloxacin in bio-fluids and tablets without prior extraction. The need for such procedures is especially important in pharmacokinetic studies of norfloxacin in plasma as well as pefloxacin, since norfloxacin is one of the metabolic products of pefloxacin.

Because the norfloxacin is a highly fluorescent compound and shows intense absorption in the ultraviolet, these properties were used for its direct determination in the serum and in tablets.

## EXPERIMENTAL

### Apparatus

Fluorescence measurements were made on Aminco SPF - 500 C spectrofluorimeter equipped with a 300 W Xenon lamp and 10 mm silica cells. Slit widths were set to 2.5 nm in both the excitation and emission monochromators; gain was adjusted to 10. UV spectra were made on Shimadzu (Japan) model 2100 double-beam, scanning spectrophotometer interfaced to data Station. Quartz cuvettes of 1 cm pathlength were used. Operating conditions were: scan speed 200 nm/ min.; time response 0.1 sec and slit width 0.5 nm.

### Reagents, solutions and samples

All reagents and solvents were of analytical grade purity. Water was doubly distilled. Norfloxacin standard, purity 100 %, was product of Sigma (USA). Tablets of norfloxacin "Nolicin" (nominally 400 mg ) were supplied by "Krka" Novo Mesto (Slovenia). Sodium-dodecylsulphate (SDS) was product of Serva (FRG); 2 % water solution was used. 0.1 M HCl and 0.05 M NaOH were prepared from Merck (Darmstad, FRG) reagents.

### Calibration graph and procedure for tablets

Stock solution of norfloxacin ( $10^{-3}$  M) was prepared by dissolving of norfloxacin standard in doubly distilled water. Different portions 0.1-0.8 mL were pipeted into a 10 mL volumetric flasks and diluted to 10 mL with 0.05 M NaOH. The second-derivative spectrum of each solution was recorded against 0.05 M NaOH as reagent blank.

Ten tablets were accurately weighed and finely powdered. An amount of the powdered tablets, equivalent to 40 mg of norfloxacin, was weighed and dissolved in water. The solution prepared was filtered and diluted with water up to 100 mL. An aliquot of sample tablet solution (0.2-0.3 mL) was used in the same procedure as described for the calibration graph.

### Calibration graph and procedure for serum samples

A human pool serum was mixed with standard solution of norfloxacin given the concentration of drug in the 0.5-8.0 mg/L range. Aliquot of 0.1 mL of prepared solutions




Fig. 2. UV spectrum of  $4 \cdot 10^{-5}$  M norfloxacin in 0.05 M NaOH (a) original spectrum, (b) second derivative

was diluted with 0.5 mL of 2% SDS solution and 1.9 mL of 0.1 M HCl. Blanks values obtained by diluting the same volume of serum. The fluorescence of each solution were measured at 455 nm (excitation wavelength 320 nm).

### Analytical recovery

Eight different concentrations of norfloxacin were added to a human serum in order to get concentrations 40–320  $\mu\text{g/L}$  of norfloxacin. These serum samples were treated according to the procedure for the calibration graph.

### Results and discussion

The fluorescence excitation and emission spectra of norfloxacin in 0.1 M HCl are shown in Fig. 2. The excitation spectrum shows four maxima at 264, 292, 315 and 325 nm with emission at 450 nm. The emission spectrum shows a maximum at 455 nm with excitation at 320 nm. The excitation at 320 nm was selected in order to minimize the serum emission. The emission at 455 nm was enhanced upon addition of SDS apparently because of the reduced binding of norfloxacin to serum proteins. Therefore SDS was added in each sample in the same concentration (0.4%) which was found, by trial and




Fig. 3. The fluorescence excitation and emission spectra of  $1.6 \cdot 10^{-6}$  M norfloxacin in 0.1 M HCl

error, to be optimal. The emission at 455 nm was chosen for analysis. The fluorescence intensity was linearly proportional to the concentration of the norfloxacin in the concentration range 20 - 320  $\mu\text{g/L}$ . The regression equation of the calibration line was:  $Y = 26.16 X + 0.89$  ( $n=10$ ,  $r = 0.9998$ ) where  $Y$  = fluorescence intensity and  $X$  = concentration of norfloxacin in  $\mu\text{g/L}$ . The detection limit, defined after J.Manes [15] was 2  $\mu\text{g/L}$ . Recovery was 99-101 %.

For the determination of norfloxacin in tablets its strong absorption in ultraviolet was used. In Fig. 3. the zeroth and second derivative spectra are shown. The uv spectrum in 0.05 M NaOH consists of 3 intense absorptions with the maxima at 277, 315 and 330 nm. Sodium hydroxide was chosen because of enhanced solubility of norfloxacin in alkaline medium. In order to avoid interference from other components in tablets, which show absorption below 300 nm, the peak at 330 nm was chosen for analysis. Because it is not well separated from the peak at 315 nm the second derivative of the spectrum was used. In second derivation inverse peak appears at 337 nm and its height peak to peak linearly varies with the concentration of the norfloxacin in the concentration range 3-30  $\mu\text{g/mL}$  with the regression equation of the line:  $Y = 3.02 \cdot 10^{-3} X + 0.85 \cdot 10^{-3}$  ( $n=10$ ,  $r=0.9999$ ).  $Y$  is the height of the peak,  $X$  is the concentration of the norfloxacin in  $\text{M/L}$ . The proposed method was applied to the determination of norfloxacin in Nolicin tablets. The relative standard deviation was 1.63-2.28 % for norfloxacin concentrations of 0.00798 - 0.01197  $\text{mg/mL}$ .

## REFERENCES

1. T. Ohkubo, M.Kubo and K.Sugavara , *Analytical Sciences* , **7**, 741 (1991)
2. A.Farina, *J. Pharm. Biomed. Anal.* , **7** (12) 1579 (1989)
3. A. Veber, M. Veber, F. Kozjek, S. Gomiscek and M. Marolt-Gomiscek, *Acta Pharm. Jugosl.*,**39** (4) 321 (1989)
4. C.Y. Chan. H.W. Lam and G.L. French, *J.Antimicrob. Chemother.*, **23**, (4) 597 (1989)
5. A. Rotar and P. Salmajer Lampic, *Acta Pharm. Jugosl.*, **39** (2) 123 (1989)
6. G.R. Rao, A.B. Avadhanulu, R. Giridhar and C.K. Kokate, *Indian Drugs*, **26** (10) 580 (1989)
7. R. Varlich, D. Krause and E. Mutschler, *Arzneim.-Forsch.*, **39** (6) 656 (1989)
8. Y. Katagiri, K. Naora, N. Ichikawa, M. Nayashibara and K. Iwamoto, *Chem. Pharm. Bull.*, **37**, (10) 2858 (1989)
9. J. Parasrampurua and V. Das Gupta, *Drug. Dev. Ind. Pharm.*, **16** (9) 1597 (1990)
10. J.F. Bauer, S. Howard and A. Schmidt, *J. Chromatogr.*, **514**, (2) 348 (1990)
11. J. Jin, Yaowu Fenxi Zazhi, **10**, (6) 362 (1990)
12. Y. K. Singh Rathore, P.K. Chatterjee, S.C. Mathur, S. Lal and P.D. Sethi, *Indian Drugs*, **27**, (5) 326 (1990)
13. D. Xu, Y. Yuan and X. Tu, Yaowu Fenxi Zazhi, **10**, (5) 265 (1990)
14. F. Gutzler, *Fortschr. Chemother.* , **6**, (10) 1897 (1987)
15. J. Manes, M.J. Gimeno, J.C. Molto and G. Font, *J. Phar. Bimed. Anal.* ,**6**, 1023 (1988)

Date Received: April 27, 1993

Date Accepted: June 8, 1993